close
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Ashvattha Therapeutics

Ashvattha Therapeutics Appoints Ophthalmology Veteran Robert J. Dempsey as Interim CEO Following Positive Phase 2 Results and FDA Alignment on Pivotal Program
From Ashvattha Therapeutics
Via GlobeNewswire
Ashvattha Therapeutics to Present Phase 2 DME and nAMD Data at Innovate Retina
From Ashvattha Therapeutics
Via GlobeNewswire
Ashvattha Therapeutics Announces Positive Topline 40-Week Phase 2 Results for Migaldendranib in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
From Ashvattha Therapeutics
Via GlobeNewswire
Ashvattha Therapeutics to Present Late-Breaking Phase 2 DME and nAMD Data at 25th EURETINA Congress
From Ashvattha Therapeutics
Via GlobeNewswire
Ashvattha Therapeutics Presents Positive Interim Phase 2 Results for Subcutaneous Migaldendranib Treatment for DME and Wet-AMD at 2025 MaculArt Meeting
From Ashvattha Therapeutics
Via GlobeNewswire
Ashvattha Therapeutics Reports the Ability to Tune Nanomedicines to Image Neuroinflammation in Multiple Sclerosis Patients and Tumor Associated Macrophages in Cancer at SNMMI Annual Meeting
From Ashvattha Therapeutics
Via GlobeNewswire
Ashvattha Therapeutics to Present Data on Novel Nanomedicine Radiotracers at SNMMI Annual Meeting
From Ashvattha Therapeutics
Via GlobeNewswire
Ashvattha Therapeutics to Present Phase 2 DME and Wet AMD Data at Clinical Trials at the Summit and MaculArt
From Ashvattha Therapeutics
Via GlobeNewswire
Ashvattha Therapeutics to Present Positive Phase 2 Results for Subcutaneous Migaldendranib in Retinal Vascular Disease at ARVO
From Ashvattha Therapeutics
Via GlobeNewswire
Ashvattha Therapeutics to Present at ARVO, Retina World Congress, and AOS Annual Meeting
From Ashvattha Therapeutics
Via GlobeNewswire
Ashvattha Therapeutics Accelerates Clinical Development Strategy with Leadership Appointment of Six Leading Retinal Specialists to Clinical Advisory Board
From Ashvattha Therapeutics
Via GlobeNewswire
Ashvattha Presents Positive Phase 2 Data for Subcutaneous Migaldendranib at Angiogenesis 2025 Conference
From Ashvattha Therapeutics
Via GlobeNewswire
Ashvattha to Present at Upcoming Angiogenesis, Exudation, and Degeneration 2025 and BIO CEO Conferences
From Ashvattha Therapeutics
Via GlobeNewswire
Ashvattha Therapeutics Announces $50 Million Financing Extension and Interim Phase 2 Ophthalmology Trial Results
From Ashvattha Therapeutics
Via GlobeNewswire
Ashvattha Therapeutics Announces Two Oral Presentations at the World Molecular Imaging Congress 2021
From Ashvattha Therapeutics
Via Business Wire
Ashvattha Therapeutics Announces Participation at Upcoming Investor Conferences
From Ashvattha Therapeutics
Via Business Wire
Ashvattha Therapeutics Announces Positive Interim Data from Ongoing Phase 2 PRANA Clinical Study of OP-101 in Severe COVID-19 Patients
From Ashvattha Therapeutics
Via Business Wire
Ashvattha Therapeutics to Present at 2021 Sachs 7th Annual Digital Immuno-Oncology Innovation Forum
From Ashvattha Therapeutics
Via Business Wire
Ashvattha Therapeutics Presents Transformative Anti-Angiogenesis Treatment for Retinal Disorders at ARVO 2021
From Ashvattha Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Starting at $3.75/week.

Subscribe Today